Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Mink Therapeutics Fiscal Q3 2024 Earnings Report - CapyFin

Mink Therapeutics

INKT · NASDAQ🇺🇸

View Company

Overview Earnings

Dividends Seasonality Metrics

Q3 2025 -1.92%Q2 2025 -13.63%Q1 2025 -3.30%Q4 2024 -3.29%Q3 2024 -5.04%Q2 2024 +0.60%Q1 2024 +6.12%Q4 2023 -2.90%Q3 2023 -11.76%Q2 2023 +1.67%Q1 2023 +13.91%Q4 2022 +0.48%Q3 2022 +14.55%Q2 2022 +13.24%Q1 2022 -26.70%Q3 2021 -6.13%Q4 2021 -6.13%Q2 2021 -42.03%Q1 2021 Q4 2020 Q3 2020 Q2 2020 Q1 2020

Nov 14, 2024

•

Sep 30, 2024

Mink Therapeutics Q3 2024 Earnings Report

MiNK Therapeutics reported third quarter 2024 results and provided a business update.

Key Takeaways

MiNK Therapeutics reported a net loss of $1.8 million, or $0.05 per share, for the third quarter of 2024. The company ended the quarter with a cash balance of $6.3 million.

MiNK is advancing clinical programs with an ongoing Phase 2 study in second-line and later-stage gastric cancer.

Initial data from the Phase 2 study in gastric cancer is anticipated early next year.

MiNK ended the quarter with a cash balance of $6.3 million.

Net loss for the quarter was $1.8 million, or $0.05 per share.

Total Revenue

EPS

-$0.05

Previous year: -$0.15